Merck’s ‘Three Pillars’ Strategy Takes Big Step With New Hangzhou Plant
This article was originally published in PharmAsia News
Executive Summary
Merck President of Global Human Health Adam Schechter talks about the company’s strategy in China and emerging markets following the opening of Merck’s $120 million plant in Hangzhou, China.